ImmunityBio (26CA) Ratios
ImmunityBio Ratios
DE:26CA's free cash flow for Q2 2026 was $-70.03M. For the 2026 fiscal year, DE:26CA's free cash flow was decreased by $-3.54M and operating cash flow was $-66.49M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.10 | 3.36 | 5.05 | 0.28 | 0.91 |
| Quick Ratio | 5.08 | 3.21 | 5.05 | 0.28 | 0.91 |
| Cash Ratio | 1.43 | 2.61 | 4.55 | 0.21 | 0.49 |
| Solvency Ratio | -0.34 | -0.45 | -0.52 | -0.49 | -0.47 |
| Operating Cash Flow Ratio | -4.94 | -7.12 | -6.29 | -0.67 | -0.74 |
| Short-Term Operating Cash Flow Coverage | -32.84 | 0.00 | 0.00 | -0.78 | -0.92 |
| Net Current Asset Value | $ -686.60M | $ -686.48M | $ -796.30M | $ -671.60M | $ -378.48M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 1.75 | 1.32 | 1.44 | 2.00 | 1.38 |
| Debt-to-Equity Ratio | -1.76 | -1.03 | -1.24 | -1.62 | -2.67 |
| Debt-to-Capital Ratio | 2.32 | 33.46 | 5.20 | 2.62 | 1.60 |
| Long-Term Debt-to-Capital Ratio | 2.49 | -16.97 | 7.21 | -1.17 | 4.77 |
| Financial Leverage Ratio | -1.00 | -0.78 | -0.86 | -0.81 | -1.94 |
| Debt Service Coverage Ratio | -1.83 | -2.01 | -5.52 | -0.73 | -1.02 |
| Interest Coverage Ratio | -2.28 | -2.61 | -4.18 | -7.45 | -22.24 |
| Debt to Market Cap | 0.46 | 0.26 | 0.27 | 0.33 | 0.26 |
| Interest Debt Per Share | 1.08 | 0.91 | 1.60 | 1.93 | 1.70 |
| Net Debt to EBITDA | -3.53 | -1.36 | -0.96 | -1.76 | -1.45 |
| Profitability Margins | |||||
| Gross Profit Margin | 99.34% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -211.04% | -1912.42% | -79931.67% | -154225.42% | -35866.17% |
| EBITDA Margin | -197.34% | -1793.37% | -76955.47% | -146617.08% | -34341.76% |
| Operating Profit Margin | -226.00% | -2334.23% | -58239.55% | -146374.17% | -35361.88% |
| Pretax Profit Margin | -310.37% | -2805.32% | -93873.31% | -173869.17% | -37456.00% |
| Net Profit Margin | -310.18% | -2804.77% | -93761.41% | -173569.58% | -37129.55% |
| Continuous Operations Profit Margin | -310.25% | -2805.32% | -93866.88% | -173883.33% | -37456.96% |
| Net Income Per EBT | 99.94% | 99.98% | 99.88% | 99.83% | 99.13% |
| EBT Per EBIT | 137.33% | 120.18% | 161.18% | 118.78% | 105.92% |
| Return on Assets (ROA) | -70.01% | -108.00% | -115.61% | -114.96% | -73.96% |
| Return on Equity (ROE) | 70.34% | 84.56% | 99.35% | 93.12% | 143.20% |
| Return on Capital Employed (ROCE) | -58.17% | -104.94% | -81.19% | 253.64% | -330.56% |
| Return on Invested Capital (ROIC) | -56.95% | -102.60% | -80.24% | -118.66% | -82.13% |
| Return on Tangible Assets | -72.02% | -112.69% | -119.66% | -121.68% | -74.18% |
| Earnings Yield | -19.29% | -23.17% | -22.84% | -20.55% | -14.65% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.66 | 5.56 | 0.20 | 0.13 | 0.70 |
| Payables Turnover | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.83 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.77 | 0.09 | 0.00 | 0.00 | 0.01 |
| Asset Turnover | 0.23 | 0.04 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.59 | 0.08 | -0.01 | -0.00 | 0.21 |
| Cash Conversion Cycle | -2804.02 | 65.67 | 1859.04 | 2874.38 | 520.93 |
| Days of Sales Outstanding | 137.31 | 65.67 | 1859.04 | 2874.38 | 520.93 |
| Days of Inventory Outstanding | 441.10 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 3382.43 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 578.41 | 65.67 | 1859.04 | 2874.38 | 520.93 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.33 | -0.56 | -0.72 | -0.84 | -0.71 |
| Free Cash Flow Per Share | -0.34 | -0.57 | -0.78 | -1.04 | -0.79 |
| Dividend Paid and CapEx Coverage Ratio | -79.29 | -56.80 | -11.99 | -4.32 | -8.18 |
| Capital Expenditure Coverage Ratio | -79.29 | -56.80 | -11.99 | -4.32 | -8.18 |
| Operating Cash Flow Coverage Ratio | -0.35 | -0.78 | -0.50 | -0.47 | -0.43 |
| Operating Cash Flow to Sales Ratio | -2.69 | -26.53 | -589.64 | -1406.29 | -293.81 |
| Free Cash Flow Yield | -16.95% | -22.30% | -15.56% | -20.50% | -13.01% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -5.21 | -4.34 | -4.38 | -4.87 | -6.82 |
| Price-to-Sales (P/S) Ratio | 16.08 | 121.07 | 4105.07 | 8447.89 | 2533.77 |
| Price-to-Book (P/B) Ratio | -3.65 | -3.65 | -4.35 | -4.53 | -9.77 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.90 | -4.48 | -6.43 | -4.88 | -7.68 |
| Price-to-Operating Cash Flow Ratio | -5.97 | -4.56 | -6.96 | -6.01 | -8.62 |
| Price-to-Earnings Growth (PEG) Ratio | 0.15 | 0.09 | -0.41 | -0.29 | -0.13 |
| Enterprise Value Multiple | -11.68 | -8.11 | -6.30 | -7.52 | -8.83 |
| Enterprise Value | 2.61B | 2.15B | 3.01B | 2.65B | 2.83B |
| EV to EBITDA | -11.68 | -8.11 | -6.30 | -7.52 | -8.83 |
| EV to Sales | 23.05 | 145.53 | 4846.66 | 11027.60 | 3031.16 |
| EV to Free Cash Flow | -8.46 | -5.39 | -7.59 | -6.37 | -9.19 |
| EV to Operating Cash Flow | -8.56 | -5.48 | -8.22 | -7.84 | -10.32 |
| Tangible Book Value Per Share | -0.56 | -0.72 | -1.19 | -1.17 | -0.63 |
| Shareholders’ Equity Per Share | -0.54 | -0.70 | -1.15 | -1.12 | -0.62 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.12 | 0.02 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.38 | -0.59 | -1.15 | -1.04 | -0.89 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 0.99 |
| Interest Burden | 1.47 | 1.47 | 1.17 | 1.13 | 1.04 |
| Research & Development to Revenue | 1.83 | 12.90 | 373.58 | 1033.95 | 209.81 |
| SG&A to Revenue | 1.30 | 11.45 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.32 | 2.34 | 79.04 | 167.41 | 61.22 |
| Income Quality | 0.87 | 0.95 | 0.63 | 0.81 | 0.79 |
Currency in USD